# Puma Biotechnology Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Puma Biotechnology Inc). ## Overview Puma Biotechnology is a U.S.-based biopharmaceutical company focused on developing and commercializing oncology therapies. Its core commercial product is NERLYNX, an oral neratinib treatment for certain HER2-positive breast cancers, and it also holds global rights to develop and commercialize alisertib, a small-molecule Aurora Kinase A inhibitor. ## Products & services • NERLYNX (oral neratinib) for HER2-positive breast cancer • Global development and commercialization of alisertib • Oncology commercialization and medical affairs support • Access, reimbursement, and patient support services - **Commercial oncology product** (89%) — Sales of NERLYNX for approved HER2-positive breast cancer indications. - **Royalty revenue** (11%) — Royalties earned from sub-licensee sales of NERLYNX in international territories. - **Drug development pipeline** (0%) — Development activities for alisertib and related clinical programs. - NERLYNX (oral neratinib) for HER2-positive breast cancer - Global development and commercialization of alisertib - Oncology commercialization and medical affairs support - Access, reimbursement, and patient support services ## Customers Puma sells NERLYNX primarily through a limited number of U.S. specialty pharmacies and specialty distributors, which then dispense the product to patients and certain medical centers or hospitals. It also earns royalty revenue from sub-licensees that commercialize NERLYNX in international territories. The business is therefore tied to oncology prescribing, payer access, and the purchasing behavior of a concentrated channel network. - **U.S. specialty pharmacies** (primary) — Buy NERLYNX for dispensing to patients under prescription and are a core channel for product revenue. - **U.S. specialty distributors** (primary) — Purchase and distribute NERLYNX into oncology care settings and support product availability. - **International sub-licensees** (secondary) — Commercialize NERLYNX in their territories and generate royalty revenue for Puma. - **Oncology prescribers and care teams** (primary) — Influence adoption by selecting NERLYNX for eligible HER2-positive breast cancer patients. - U.S. specialty pharmacies that purchase and dispense NERLYNX - Specialty distributors that resell into oncology channels - Patients and medical centers reached through pharmacy distribution - Sub-licensees that commercialize NERLYNX outside the U.S. - Oncologists and care teams influence prescribing and uptake ## Geography Puma is headquartered in the United States and its direct commercial operations are centered there, where it maintains an oncology sales force and related commercial infrastructure. Outside the U.S., the company participates through sub-license arrangements that generate royalty revenue from international territories, including sales activity in China. Geography matters because reimbursement, pricing, and regulatory approval differ by market and directly affect uptake. - United States is the main direct commercial market for NERLYNX - U.S. sales force supports oncologists, access, and reimbursement - International revenue comes mainly from sub-licensee territories - China is an important source of royalty revenue exposure - Drug pricing and reimbursement rules vary materially by country ## Strategy Puma’s strategy centers on extending NERLYNX commercialization while funding development of alisertib as a second oncology asset. The company also relies on third-party manufacturing, regulatory, and distribution partners, so execution depends on maintaining supply, access, and clinical progress across a narrow product base. - **Commercialize NERLYNX in the U.S.** (short-term) — The product is the company’s main revenue engine and requires payer access and physician adoption. - **Advance alisertib development** (medium-term) — A second oncology asset could diversify the business beyond a single commercial product. - **Maintain international partnering model** (medium-term) — Sub-license arrangements provide royalty revenue without building a large overseas commercial footprint. - Maximize NERLYNX uptake in HER2-positive breast cancer - Expand alisertib development in selected oncology indications - Support physician education and payer access for adoption - Use sub-license partnerships to reach international markets - Depend on third-party manufacturing and supply partners ## Risks Puma is exposed to concentrated product and customer risk because most revenue depends on NERLYNX and a limited number of specialty channel customers. It also faces clinical, regulatory, manufacturing, and reimbursement risk typical of oncology biopharma, where competitor products, pricing pressure, and trial outcomes can quickly alter commercial prospects. - **Customer concentration** [high] — A limited number of specialty pharmacies and distributors account for a large share of product revenue, so losing one can materially affect sales. - **Competitive pressure in oncology** [high] — Other approved or emerging therapies may offer better safety, efficacy, convenience, pricing, or reimbursement access. - **Development and regulatory risk** [high] — Alisertib depends on successful clinical development and regulatory approval before it can become a meaningful product. - **Manufacturing and supply dependence** [medium] — The company relies on third-party contractors for drug substance, drug product, storage, and distribution. - **International royalty exposure** [medium] — Royalty revenue depends on sub-licensee sales in foreign markets, which can fluctuate with local demand and competition. - Revenue concentration in one main product increases business risk - A small number of customers account for a large share of sales - Competition may reduce NERLYNX adoption or pricing power - Clinical or regulatory setbacks could impair alisertib development - Third-party manufacturing and supply chain dependence can disrupt supply ## Accounting Revenue recognition is central to Puma’s reporting because product sales are recorded net of rebates, chargebacks, discounts, and other variable consideration, while royalty revenue is recognized when sub-licensee sales occur. Investors should also watch estimates around tax valuation allowances, contingent milestone obligations, and legal or tax reserves, because these judgments can materially affect earnings and balance sheet presentation. - **Gross-to-net revenue reserves** — Affects product revenue timing and net sales margin - **Royalty revenue recognition** — Affects quarterly and annual revenue volatility - **Valuation allowance on deferred tax assets** — Can materially affect net income - **Milestone obligations and contingencies** — Affects liabilities and future cash outflows - **Legal and tax reserves** — Affects accrued liabilities and earnings - Net product revenue depends on gross-to-net reserve estimates - Royalty revenue is recognized when sub-licensee sales occur - Customer rebates and chargebacks affect reported sales - Tax valuation allowance changes can swing net income - Milestone and legal contingencies require judgment and accruals --- *Last updated: 2026-09-24T11:43:53.417648+00:00*